StockData
Attovia Therapeutics, Inc. logo

Attovia Therapeutics, Inc. (ATTO) stock

ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$15.58+0.05 (+0.32%)

Close on Nov 19, 2026Market cap $711.25MP/E –Yield –

Attovia Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.69M–
Q3 FY2025Sep 30, 2025-$15.53M–

More Attovia Therapeutics figures

See a number that looks wrong?